Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14941MR)

This product GTTS-WQ14941MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14941MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9179MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ15317MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ12078MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ8065MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ9161MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ15392MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ11151MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ6056MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO 136
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW